Compare Mondaycom Ltd (MNDY) vs Novartis AG (NVS) Price & Performance

Monday.com (MNDY) trades at $85.95, down 3.01% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $1.48 versus $1.11 expected, and revenue growth of 22% year-over-year. However, weak Q3 revenue guidance has triggered a sell-off. Technical indicators are neutral with support at $83 and resistance at $89. Analyst consensus remains bullish with a $113.38 price target.

Outlook is cautiously optimistic due to robust earnings beats and AI product growth, but near-term risks include slower revenue guidance and competitive pressures. The high P/E of 37.04 suggests premium valuation, demanding sustained execution. Investors should weigh strong profitability against guidance concerns for balanced exposure.

Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.

The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.